- Home
- NOC vs REGN Comparison
NOC vs REGN Comparison
Compare NOC & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NOC
- REGN
- Stock Information
- Founded
- NOC 1939
- REGN 1988
- Country
- NOC United States
- REGN United States
- Employees
- NOC N/A
- REGN N/A
- Industry
- NOC Industrial Machinery/Components
- REGN Biotechnology: Pharmaceutical Preparations
- Sector
- NOC Industrials
- REGN Health Care
- Exchange
- NOC Nasdaq
- REGN Nasdaq
- Market Cap
- NOC 70.9B
- REGN 63.4B
- IPO Year
- NOC N/A
- REGN 1991
- Fundamental
- Price
- NOC $540.39
- REGN $563.16
- Analyst Decision
- NOC Buy
- REGN Buy
- Analyst Count
- NOC 18
- REGN 23
- Target Price
- NOC $554.71
- REGN $971.57
- AVG Volume (30 Days)
- NOC 1.1M
- REGN 1.1M
- Earning Date
- NOC 04-22-2025
- REGN 04-29-2025
- Dividend Yield
- NOC 1.53%
- REGN 0.16%
- EPS Growth
- NOC 109.46
- REGN 10.27
- EPS
- NOC 28.34
- REGN 38.34
- Revenue
- NOC $41,033,000,000.00
- REGN $14,202,000,000.00
- Revenue This Year
- NOC $4.18
- REGN $4.06
- Revenue Next Year
- NOC $4.64
- REGN $6.54
- P/E Ratio
- NOC $19.07
- REGN $14.69
- Revenue Growth
- NOC 4.44
- REGN 8.27
- 52 Week Low
- NOC $418.60
- REGN $525.99
- 52 Week High
- NOC $555.57
- REGN $1,211.20
- Technical
- Relative Strength Index (RSI)
- NOC 67.30
- REGN 37.15
- Support Level
- NOC $480.90
- REGN $544.50
- Resistance Level
- NOC $538.68
- REGN $575.20
- Average True Range (ATR)
- NOC 16.65
- REGN 28.44
- MACD
- NOC 2.77
- REGN -1.59
- Stochastic Oscillator
- NOC 93.91
- REGN 32.25
About NOC Northrop Grumman Corporation
Northrop Grumman Corp is a diversified company which is aligned in four operating sectors, which also comprise our reportable segments namely Aeronautics Systems, Defense Systems, Mission Systems and Space Systems. The aerospace segment designs and builds military aircraft, including the F-35, Global Hawk drones, and the B-21 bomber. Defense systems develops artillery, missile systems, and missile defense technologies. Mission systems focuses on radar, navigation, and communication systems, while space systems manufactures satellites, sensors, and rocket motors.
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).